动脉样硬化中的PPAR:从机制到可药物点的空间和时间特征
Yi Zheng1, Mingyan Shao2, Yanfei Zheng2
1School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Journal of advanced research
|March 30, 2024
概括
过氧体增殖器激活受体 (PPAR) 通过向特定的细胞和疾病阶段,提供精确的抗动脉样硬化疗法. PPAR调节剂和激动剂在未来的心血管药物开发方面表现有前途.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 动脉样硬化是一种复杂的慢性疾病,与全球心血管死亡率有关.
- 脂质障碍和炎症是动脉样硬化病原的关键驱动因素.
- 过氧体增殖器激活受体 (PPAR) 是抗动脉样硬化策略的关键目标.
研究的目的:
- 系统地审查PPAR在动脉样硬化中的作用,跨病理阶段和细胞类型.
- 探索PPAR的药理和临床研究,以准确的治疗策略.
- 为新药开发提供洞察力,针对动脉样硬化治疗的PPAR.
主要方法:
- 关于动脉样硬化的空间和时间特征的文献综述.
- 分析PPAR在内皮细胞,巨细胞和血管光滑肌细胞中的功能.
- 对选择性PPAR调节剂和PPAR泛激动剂的评估.
主要成果:
- PPARs调节内皮功能障碍,巨细胞脂质代谢和VSMC增殖.
- 选择性PPAR调节剂提供组织和细胞特异性效应.
- PPAR-pan激动剂显示出平衡疗效和减少副作用的潜力.
结论:
- 针对PPAR的阶段和细胞类型依赖的精确疗法对动脉样硬化至关重要.
- 了解细胞特异性PPAR机制有助于量身定制的药物开发.
- 基于PPAR的疗法,包括调节剂和激动剂,为心血管疾病治疗提供了一个有希望的途径.
相关概念视频
Structure-Activity Relationships and Drug Design
716
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
716
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
38
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
38
Targets for Drug Action: Overview
6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K


